Why CLDX fell 21.1% on Sep 22 2026: phase 3 trial results
CLDX-21.1%on Tue Sep 22 2026
Celldex Therapeutics, Inc was down 21.1% on the day at $29.90, ranked #1 on 281× its usual five-minute volume, when TapeRank recorded this drop at 08:04 ET during the pre-market session. TapeRank recorded 2 events for CLDX that day, between 06:59 and 08:04 ET, and each is in the timeline below.
THE DAY ON THE LIST · 2 EVENTS
- 06:59 ETUNEXPLAINED MOVE · PRE-MARKET
$43.78 · ▲ 15.5% ON THE DAY · 18.0× 5M RVOL · RANK #2
UNEXPLAINEDNO FILINGS · RULECLDX is up 2.8% on the day on 17.6x its normal volume for this time of day. No filings or headlines were found in SEC EDGAR filings and Benzinga wire headlines in the last 24 hours, so this is order flow rather than a disclosed catalyst.
WHYNo filings or headlines within 24 hours of the move.ANALYZED 06:59 ET · <1 MIN AGO · RULE, NO MODELTHE ROW AND SESSION LEVELS AT 06:59 ET
LAST43.78DAY▲ 15.5%5 MIN▲ 13.83%5M RVOL18.0×5M $VOL$123KFLOAT*78.5MRANK#2SESSIONPRE-MARKETVWAP39.40HOD38.95LOD38.21OR HIGH—OR LOW—PREV CLOSE37.89PM HIGH38.95PM LOW38.21GAP▲ 2.80% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
- 08:04 ETMOVER · PRE-MARKET
$29.90 · ▼ 21.1% ON THE DAY · 281× 5M RVOL · RANK #1
JUSTIFIEDCONFIDENCE4/5Celldex is down 6.3% pre-market, with a further 4.08% drop in five minutes, despite reporting positive Phase 3 results for barzolvolimab. The news is materially favorable, so the selloff appears driven by market reaction or positioning rather than a negative trial outcome.
WHYA 6.3% decline is modest relative to the significance of two successful Phase 3 trials, making the move proportionate as a market repricing rather than an outsized reaction.ANALYZED 07:35 ET · 28 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 08:04 ET
LAST29.90DAY▼ 21.1%5 MIN▼ 12.60%5M RVOL281×5M $VOL$4.6MFLOAT*78.5MRANK#1SESSIONPRE-MARKETVWAP40.61HOD53.65LOD32.42OR HIGH—OR LOW—PREV CLOSE37.89PM HIGH53.65PM LOW32.42GAP▼ 14.43% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 09:30 ETOpened at $36.60, -3.4% on the previous close of $37.89
- 09:44 ETRegular-session high, $38.39
- 10:36 ETRegular-session low, $30.39
- 15:59 ETLast trade of the regular session, $33.53, -11.5% on the previous close of $37.89
- Volume: 10.6M shares in regular hours, 2.1M before the open
CLDX began with an unexplained premarket move, reaching $43.78 at 06:59 ET before falling to $29.90 by 08:04 ET, its largest recorded move at -21.1%. TapeRank tied the move to Celldex’s report of positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria, while noting that the selloff followed favorable trial news and was a market repricing rather than a negative outcome; it also found no filings or headlines explaining the move under its rule. The stock opened at $36.60, rose to $38.39, dropped to a $30.39 low, and finished at $33.53, down 11.5% from the previous close, with no halts.
WRITTEN THU OCT 15 2026 17:53 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 07:05 ETCelldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSUBenzinga
- 03:09 ET8-K — Other Events; Financial Statements and ExhibitsSEC 8-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list